<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytogenetic evaluation of bone marrow and neoplastic tissues plays a critical role in determining patient management and prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we highlight two cases in which the cytogenetic studies challenge the common practice of using hematologic and morphologic changes as key factors in malignant disease management </plain></SENT>
<SENT sid="2" pm="."><plain>The first case is that of a lymph node sample from a 40-yr-old non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) patient sent for determination of disease progress </plain></SENT>
<SENT sid="3" pm="."><plain>Hematologic studies showed no evidence of transformation to high-grade NHL (&gt;15% blasts with rare mitotic figures) </plain></SENT>
<SENT sid="4" pm="."><plain>Cytogenetic studies of lymph node showed multiple clonal abnormalities, most notably a der(18) from a t(14;18) which is associated with high-grade NHL </plain></SENT>
<SENT sid="5" pm="."><plain>After two cycles of chemotherapy with fludarabine, the patient did not show any clinical response, suggesting possible progression to high-grade <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The second case is of a patient with a history of human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus and blastic natural killer <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Hematologic studies of ascitic fluid classified the patient as having <z:hpo ids='HP_0002202'>pleural effusion</z:hpo> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> whereas bone marrow analysis showed no <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="9" pm="."><plain>To our knowledge, this is the first case wherein a morphologically <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow showed presence of clonal abnormalities consistent with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> or <z:hpo ids='HP_0002202'>Pleural effusion</z:hpo> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>After two cycles of CHOP (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi> and <z:chebi fb="0" ids="8382">prednisone</z:chebi>) chemotherapy, the patient's general condition and ascitis improved and she was discharged </plain></SENT>
<SENT sid="11" pm="."><plain>These studies clearly demonstrate that genetic changes often precede morphologic changes in a developing malignant condition </plain></SENT>
<SENT sid="12" pm="."><plain>Therefore, the critical information needed for care of patients with malignant disorders may be incomplete or inaccurate if cytogenetic evaluation is overlooked </plain></SENT>
</text></document>